What is a PANDEMIC?
Today it is the COVID19 viral infection
Yesterday, cancer was already a pandemic disease
Tomorrow, chronic illness as diabetes will be the next pandemic issue
First validation of the Exscalate approach was obtained in the identification of active compounds against Zyka virus. For this project the drug-like and natural products subgroups of the tangible chemistry database have been screened on the 7 Zyka proteins for a total of 13 binding sites. The repurposing approach identified the Dactosinib as active compound with a positive proof of concept in the animal models in three months from the beginning of the screenings. The following activities on de novo chemical compounds identified at the date a new class of compounds with 2 in vitro active compounds which will be characterized further in a conventional drug development process.
Due to the exceptional medical need in the covid 19 pandemic, Excalate adopted a repurposing approach to identify active, ready to use in humans drugs. The drug-like and natural products subgroups of the tangible chemical space database have been tested against 12 Covid19 proteins for a total of 15 binding sites. One drug has been selected for its overall characteristics: Raloxifene. Raloxifene has been characterized in vitro and in vivo and it’s now in clinical testing in Italy, in six months from the first computational screening. Additionally three other back-up molecules validated to inhibit ACE2 are now in preclinical testing.